Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trialNicholas C. Turner, Alistair Ring, Peter Stephens et al.|The Lancet Oncology|2020Cited by 351
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy ResistanceAlex Pearson, Nicholas C. Turner, Paula Proszek et al.|Clinical Cancer Research|2019Cited by 137
Genomic profile of advanced breast cancer in circulating tumour DNABelinda Kingston, Nicholas C. Turner, Rosalind Cutts et al.|Nature Communications|2021Cited by 95
<i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i> -Mutant Breast CancerBelinda Kingston, Nicholas C. Turner|Cancer Discovery|2023Cited by 35